Biopharmaceutical Evaluation of Salicylazosulfanilic Acid as a Novel Colon-Targeted Prodrug of 5-Aminosalicylic Acid

References

• J. Brown, G. McGarraugh, T. Parkinson, R. Wingard, A. Onderdonk. (1983). A polymeric drug for treatment of inflammatory bowel disease J. Med. Chem. 26:1300–1307.
   PubMed Web of Science ®Google Scholar
• R. Chan, D. Pope, A. Gilbert, P. Sacra, J. Baron, J. LennardJones. (1983). Studies of two novel sulfasalazine analogs ipsalazide and balsalazide Digest. Dis. Sci. 28:609–615.
   PubMed Web of Science ®Google Scholar
• V. Chungi, G. Rekhi, L. Shargel. (1989). A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids J. Pharm. Sci. 78:235–238.
   PubMed Web of Science ®Google Scholar
• CO. Cowan, K. Das, M. Eastwood. (1977). Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis Brit. Med. J. 2:1057–1059.
   PubMed Web of Science ®Google Scholar
• K. Das, R. Dubin. (1976). Clinical pharmacokinetics of sulphasalazine Clin. Pharmacokin. 1:406–425.
   PubMed Web of Science ®Google Scholar
• K. Das, M. Eastwood, J. McManus, W. Sircus. (1973). Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype New Eng. J. Med. 289:491–495.
   PubMed Web of Science ®Google Scholar
• C. Fischer, K. Maier, U. Klotz. (1983). Specific measurements of 5aminosalicylic acid and its acetylated metabolite in human bile Brit. J. Clin. Pharmacol 15:273–274.
   PubMed Web of Science ®Google Scholar
• R. Gingell, J. Bridges, R. Williams. (1971). The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat Xenobiotica 1:143–156.
   PubMedGoogle Scholar
• P. Van Hees, J. Bakker, J. van Tongeren. (1980). Effect of sulphapyridine, 5aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine Gut 21:632–635.
   PubMed Web of Science ®Google Scholar
• R. Van Hogezand. (1988). Pharmacokinetics of olsalazine and its metabolites Scand. J. Gastroenterol. 23:17–20.
   Web of Science ®Google Scholar
• K. Kakemi, H. Sezaki, R. Konishi, T. Kimura, M. Murakami. (1970a). Effect of bile salts on the gastrointestinal absorption of drugs. I Chem. Pharm. Bull. 18:275–280.
   PubMed Web of Science ®Google Scholar
• K. Kakemi, H. Sezaki, R. Konishi, T. Kimura, A. Okita. (1970b). Effect of bile salts on the gastrointestinal absorption of drugs. II. Mechanism of the enhancement of the intestinal absorption of sulfaguanidine by bile salts Chem. Pharm. Bull. 18:1034–1039.
   PubMed Web of Science ®Google Scholar
• A. Khan, M. Nurazzaman, S. Truelove. (1983). The effect of the acetylator phenotype on the metabolism of sulphasalazine in man J. Med. Genet. 20:30–36.
   PubMed Web of Science ®Google Scholar
• A. Khan, J. Piris, S. Truelove. (1977). An experiment to determine the active therapeutic moiety of sulphasalazine Lancet 2:892–895.
   PubMed Web of Science ®Google Scholar
• A. Khan, S. Truelove, J. Aronson. (1982). The disposition and metabolism of sulphasalazine salicylazosulfapyridine in man Brit. J. Clin. Pharmacol. 13:523–528.
   PubMed Web of Science ®Google Scholar
• U. Klotz, K. Maier, C. Fischer, K. Heinkel. (1980). Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease New Eng. J. Med. 303:1499–1502.
   PubMed Web of Science ®Google Scholar
• B. Myers, D. Evans, J. Rhodes, B. Evans, B. Hughes, M. Lee, A. Richens, D. Richards. (1987). Metabolism and urinary excretion of 5aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract Gut 28:196–200.
   PubMed Web of Science ®Google Scholar
• O. Nielsen, S. Bondesen. (1983). Kinetics of 5aminosalicylic acid after jejunal instillation in man Brit. J. Clin. Phamacol. 16:738–740.
   PubMed Web of Science ®Google Scholar
• M. Peppercorn. (1990). Advances in drug therapy for inflammatory bowel disease Ann. Int. Med. 112:50–60.
   PubMed Web of Science ®Google Scholar
• M. Peppercorn, P. Goldman. (1972). The role of intestinal bacteria in the metabolism of salicylazosulfapyridine J. Pharmacol. Exp. Ther. 181:555–562.
   PubMed Web of Science ®Google Scholar
• M. Peppercorn, P. Goldman. (1973). Distribution studies of salicylazosulfapyridine and its metabolites Gastroenterology 64:240–245.
   PubMed Web of Science ®Google Scholar
• H. Pieniaszek, T. Bates. (1979). Capacitylimited gut wall metabolism of 5aminosalicylic acid, a therapeutically active metabolite of sulfasalazine in rats J. Pharm. Sci. 68:1323–1325.
   PubMed Web of Science ®Google Scholar
• H. Schroder, D. Campbell. (1972). Absorption, metabolism, and excretion of salicylazosulfapyridine in man Clin. Pharmacol. Ther. 13:539–551.
   PubMed Web of Science ®Google Scholar
• H. Schroder, D. Evans. (1972). Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects Gut 13:278–284.
   PubMed Web of Science ®Google Scholar
• N. Svartz. (1942). Salazopyrin, a new sulfanilamide preparation Acta Med. Scand. 110:577–598.
   Google Scholar
• S. Taffet, K. Das. (1983). Sulfasalazineadverse effects and desensitization Digest. Dis. Sci. 28:833–842.
   PubMed Web of Science ®Google Scholar
• K. Yamaoka, T. Nakagawa, T. Uno. (1978). Statistical moments in pharmacokinetics J. Pharmacokin. Biopharm. 6:547–558.
   PubMedGoogle Scholar
• M. Yasuhara, Y. Kurosaki, T. Kimura, H. Sezaki. (1984). Drug elimination function of rat small intestine: Metabolism and intraluminal excretion Biochem. Pharmacol. 33:3131–3136.
   PubMed Web of Science ®Google Scholar